TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 616357443
Drug: VesiGel 0.06%
Approvals — FDA: no, EMA: no, PMDA: no
Description: VesiGel 0.06% (40mg at 64mL gel; n=20)
Study: 616357443
Drug: VesiGel 0.12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: VesiGel 0.12% (80mg at 64mL gel; n=22)
Study: 35368016
Drug: Kinesiology tape
Normalized name: kinesiology tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesiology tape decompression/fan application with standard therapy
Study: 35368016
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with no kinesiology tape (Control)
Study: 35718440
Drug: 2% curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% curcumin gel
Study: 34716525
Drug: Sequential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential group (continuous circular lesions created counter-clockwise starting from the site of 6 o'clock)
Study: 32619497
Drug: Metformin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin prescription
Study: 32619497
Drug: T2DM without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T2DM without metformin prescription
Study: 36384562
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (hydroxychloroquine, sulphasalazine, and methotrexate) (TRIPLE)
Study: 37982966
Drug: Methotrexate monotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate monotherapy (MTX)
Study: 35704559
Drug: Azithromycin (AZM:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (AZM: 250mg), once-weekly weight-based dose of 1-5 tablets, taken orally.
Study: 34413300
Drug: Neoadjuvant immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant immune checkpoint inhibitors (ICIs)
Study: 32571649
Drug: Low Level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Level Laser Therapy (LLLT) with passive self-ligating brackets
Study: 32571649
Drug: Low Level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Level Laser Therapy (LLLT) with conventional brackets
Study: 35817323
Drug: 12 Gy/4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 Gy/4 fractions/4 days (for sequential boost)
Study: 34673895
Drug: 12 mg/d
Normalized name: EMSAM 12 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/d of intravenous dexamethasone
Study: 34673895
Drug: 6 mg/d
Normalized name: EMSAM 6 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/d of intravenous dexamethasone
Study: 32372161
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solution (5%) 4 times daily for 14 days
Study: 32372161
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solution (5%)
Study: 32540553
Drug: Trastuzumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (4 mg/kg, biweekly) plus oral capecitabine (1500 mg/daily) and cyclophosphamide (50 mg/daily)
Study: 35279890
Drug: Brodalumab 210
Normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 210 mg after brodalumab 140 mg or placebo
Study: 35793047
Drug: Once-daily alogliptin/metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily alogliptin/metformin combination tablet (alogliptin 25 mg/metformin 500 mg)
Study: 35793047
Drug: Twice-daily anagliptin/metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily anagliptin/metformin combination tablet low dose (anagliptin 100 mg/metformin 250 mg)
Study: 32066254
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus CRL1332, L. gasseri CRL1256 and CRL1320
Study: 36353762
Drug: Amenamevir 1200
Normalized name: amenamevir
DrugBank: Amenamevir (DB11701)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Amenamevir 1200 mg
Study: 33685864
Drug: Etelcalcetide 5
Normalized name: etelcalcetide 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etelcalcetide 5 mg thrice weekly
Study: 33685864
Drug: Maxacalcitol 5
Normalized name: paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maxacalcitol 5 or 10 µg thrice weekly
Study: 33761804
Drug: Open label
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label once daily subcutaneous vosoritide combined with standard of care
Study: 35276810
Drug: Ferrous bisglycinate
Normalized name: FERROUS BISGLYCINATE
DrugBank: Ferrous bisglycinate (DB11210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous bisglycinate (equiv. iron 24 mg) with folinic acid and multivitamins (test group, n = 60)
Study: 35276810
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous fumarate (equiv. iron 66 mg, control group, n = 60)
Study: 32833549
Drug: Routine Treatment
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Treatment (RT)
Study: 34865586
Drug: G100 20
Normalized name: G100
DrugBank: G100 (DB17244)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G100 20 µg/dose
Study: 35939812
Drug: Opioid Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid Agonist Therapy (OAT)
Study: 35303190
Drug: Telephone-Delivered Acceptance
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-Delivered Acceptance and Commitment Therapy (ACT) intervention for hazardous drinking
Study: 32757446
Drug: Intravenous Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Meloxicam
Study: 34609029
Drug: Crocin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocin (30 mg, two tablets of 15 mg per day for 8 weeks)
Study: 33681988
Drug: AMH modulation
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AMH modulation (recombinant human AMH protein supplementation during the secondary-to-early antral stage followed by neutralizing anti-human AMH antibody)
Study: 34053095
Drug: Leaflet-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leaflet-based intervention ‘Hypos can strike twice’ provided by ambulance personnel
Study: 34053095
Drug: Leaflet-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leaflet-based intervention ‘Hypos can strike twice’
Study: 38940435
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg weekly
Study: 34076641
Drug: Buccal pedicle
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal pedicle flap
Study: 32364756
Drug: TGC perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGC perfusion chemotherapy
Study: 32364756
Drug: Sunitinib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib + TGC perfusion chemotherapy
Study: 35686189
Drug: Online remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online remote behavior therapy
Study: 35686189
Drug: Face-to-face behavior
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face behavior therapy
Study: 32856190
Drug: FA +
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FA + DHA (FA 800 μg/d + DHA 800 mg/d)
Study: 32856190
Drug: FA (FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: FA (FA 800 μg/d)
Study: 32856190
Drug: DHA (DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (DHA 800 mg/d)
Study: 36458132
Drug: 0.1% menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% menthol gel
Study: 36458132
Drug: 0.3% menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% menthol gel
Study: 36458132
Drug: 0.7% menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7% menthol gel
Study: 36458132
Drug: All menthol
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All menthol gels
Study: 33431262
Drug: Pain-analgesics treatment
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain-analgesics treatment
Study: 33431262
Drug: Pain-no analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain-no analgesics
Study: 33431262
Drug: No pain-analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pain-analgesics treatment
Study: 33431262
Drug: No pain-no
Normalized name: Biochemistry Heel No Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pain-no analgesics
Study: 34057124
Drug: Dorsata honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsata honey (DH) given orally three times a day at a dose of 15 ml
Study: 36113170
Drug: Intrathecal cell
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal cell treatments (NurOwn®)
Study: 32507446
Drug: Phytosomal curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosomal curcumin (250 mg/day) for 8 weeks
Study: 32424878
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT-I)
Study: 34980598
Drug: Fulvestrant plus
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant plus sapanisertib 4 mg daily
Study: 34980598
Drug: Fulvestrant plus
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant plus sapanisertib 30 mg weekly
Study: 34980598
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg (control)
Study: 32127847
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron weight adjusted dosing at 0.1mg/kg
Study: 32127847
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 4mg ondansetron
Study: 34477818
Drug: Avelumab (anti-PD-L1)
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab (anti-PD-L1) administered at various doses: 70 mg, 350 mg, 500 mg every 2 weeks; 500 mg every 3 weeks; and 10 mg/kg every 2 weeks.
Study: 34477818
Drug: Avelumab (anti-PD-L1)
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab (anti-PD-L1) administered at various doses.
Study: 33791349
Drug: Routine oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oxygen therapy
Study: 39082471
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (ACEi)
Study: 32586079
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi exercise for 30 minutes, 5 times weekly for 48 weeks
Study: 32586079
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi exercise for 60 minutes, 5 times weekly for 48 weeks
Study: 32046755
Drug: Prophylactic augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic augmentation of the wound with absorbable mesh
Study: 32957336
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of standard triple therapy (STT) using ilaprazole (10 mg ilaprazole, 500 mg clarithromycin, and 1000 mg amoxicillin twice daily)
Study: 32957336
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of standard triple therapy (STT) using ilaprazole (10 mg ilaprazole, 500 mg clarithromycin, and 1000 mg amoxicillin twice daily)
Study: 35148357
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg for 12 weeks
Study: 36324245
Drug: MD-7246 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD-7246 300 μg
Study: 36324245
Drug: MD-7246 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD-7246 600 μg
Study: 36324245
Drug: MD-7246 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD-7246 1200 μg
Study: 33632268
Drug: Pediatric integrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric integrative manual therapy (PIMT) combined with caregiver education program
Study: 35043692
Drug: Hyperglycemia (≥180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (≥180 mg/dL)
Study: 35043692
Drug: Normoglycemia (<180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoglycemia (<180 mg/dL)
Study: 33249498
Drug: Reduced nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced nicotine content (RNC) study cigarettes tapered every three weeks to a final VLNC (0.2 mg/cigarette) for six weeks
Study: 33249498
Drug: Usual nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual nicotine content (UNC) study cigarettes (11.6 mg/cigarette)
Study: 32236521
Drug: 4-Cl-KYN monotherapy
Normalized name: Decamethylenebis(4-aminoquinaldinium chloride)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-Cl-KYN monotherapy (1080 mg/d for 7 days, then 1440 mg/d for 7 days)
Study: 35291408
Drug: Normal to
Normalized name: PROGAINE NORMAL TO DRY SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal to low blood pressure (MAP deliberately controlled at a tight limit from normal baseline MAP values to 20% less than baseline by titrating TNG infusion)
Study: 32087031
Drug: Freeze-dried German
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried German chamomile tea capsules
Study: 34111992
Drug: Landmark-guided injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Landmark-guided injection of 40 mg methylprednisolone plus 1 mL lidocaine
Study: 34111992
Drug: Ultrasonography-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonography-guided injection of 40 mg methylprednisolone plus 1 mL lidocaine
Study: 34111992
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between landmark-guided and ultrasonography-guided injections
Study: 33164580
Drug: Nicotine e‐cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine e‐cigarette (59 mg/mL)
Study: 33164580
Drug: Placebo e‐cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo e‐cigarette (0 mg/mL)
Study: 35321823
Drug: Ticagrelor in
Normalized name: Product containing ticagrelor in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor in addition to aspirin
Study: 36270493
Drug: Ticagrelor in
Normalized name: Product containing ticagrelor in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor in addition to aspirin (THEMIS-PCI substudy)
Study: 33962511
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) including rib raising and suboccipital release in addition to standard asthma care.
Study: 33077567
Drug: Exogenous surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous surfactant therapy (Curosurf, Chiesi Pharmaceuticals, Italy)
Study: 33077567
Drug: Exogenous surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous surfactant therapy (Curosurf)
Study: 34410414
Drug: Personalized antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized antiplatelet therapy (PFT-guided)
Study: 33750034
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1000 mg twice daily for 14 weeks
Study: 35567420
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product of rosuvastatin 10 mg
Study: 35567420
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product of rosuvastatin 10 mg
Study: 35567420
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of rosuvastatin 10 mg
Study: 34340936
Drug: Endometrial preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial preparation with GnRH agonist pre-treatment (group A)
Study: 34340936
Drug: Endometrial preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial preparation without GnRH agonist pre-treatment (group B)
Study: 36182028
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 1200 mg TID
Study: 35268481
Drug: Subetta therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subetta therapy for 12 weeks
Study: 34534272
Drug: Ciraparantag 30
Normalized name: Ciraparantag
DrugBank: Ciraparantag (DB15199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciraparantag 30 mg
Study: 34534272
Drug: Ciraparantag 60
Normalized name: Ciraparantag
DrugBank: Ciraparantag (DB15199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciraparantag 60 mg
Study: 34534272
Drug: Ciraparantag 120
Normalized name: Ciraparantag
DrugBank: Ciraparantag (DB15199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciraparantag 120 mg
Study: 34534272
Drug: Ciraparantag 30
Normalized name: Ciraparantag
DrugBank: Ciraparantag (DB15199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciraparantag 30 mg (rivaroxaban)
Study: 34534272
Drug: Ciraparantag 60
Normalized name: Ciraparantag
DrugBank: Ciraparantag (DB15199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciraparantag 60 mg (rivaroxaban)
Study: 34534272
Drug: Ciraparantag 120
Normalized name: Ciraparantag
DrugBank: Ciraparantag (DB15199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciraparantag 120 mg (rivaroxaban)
Study: 34534272
Drug: Ciraparantag 180
Normalized name: Ciraparantag
DrugBank: Ciraparantag (DB15199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciraparantag 180 mg (rivaroxaban)
Study: 34694215
Drug: Adapted smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted smoking cessation treatment
Study: 35941622
Drug: Pulmonary rehabilitation
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary rehabilitation sessions (twice weekly for six weeks) consisting of supervised stretching, aerobic and strengthening exercises, and patient education.
Study: 34397727
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 1.0 ng/mL
Study: 34397727
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 2.0 ng/mL
Study: 33284965
Drug: ω‐3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 supplementation (3 g/d)
Study: 33026449
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus icotinib (125 mg 3 times a day)
Study: 32740079
Drug: Low-volume same-day
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume same-day PEG (15 mg bisacodyl the day before, 2 L the morning of the procedure)
Study: 32740079
Drug: Low-volume split-dose
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume split-dose PEG (15 mg bisacodyl the day before, 1 L + 1 L)
Study: 32740079
Drug: Low-volume split-dose
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume split-dose PEG
Study: 32740079
Drug: High-volume split-dose
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume split-dose PEG
Study: 33607823
Drug: External application
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External application of mirabilite and rhubarb combined with intrathoracic chemotherapy (cisplatin)
Study: 34532785
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent epidural bolus (PIEB) 3 mL bolus every 60 min
Study: 34532785
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (CEI) 3 mL/h
Study: 32406659
Drug: Implant-supported fixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported fixed complete dentures
Study: 34370166
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health educational intervention via WhatsApp messenger for 7 weeks on a daily schedule
Study: 33999786
Drug: D/C/F/TAF 800/150/200/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: D/C/F/TAF 800/150/200/10 mg
Study: 35691295
Drug: FINLAY-FR-1A vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FINLAY-FR-1A vaccine (50 μg of recombinant dimeric receptor binding domain [RBD])
Study: 35691295
Drug: FINLAY-FR-1A vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FINLAY-FR-1A vaccine
Study: 35691295
Drug: Placebo (vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vaccine excipient)
Study: 33023516
Drug: General beliefs
Approvals — FDA: no, EMA: no, PMDA: no
Description: General beliefs about medication
Study: 33067298
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus an enhanced rehabilitation programme (patient-held information workbook, goal setting diary, up to six additional therapy sessions)
Study: 32785589
Drug: Imipenem/cilastatin/relebactam 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin/relebactam 500 mg/500 mg/250 mg
Study: 32785589
Drug: Piperacillin/tazobactam 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam 4 g/500 mg
Study: 36649072
Drug: Anti-PD-1 therapy
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 therapy
Study: 33122393
Drug: MCSFA-HFD (diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCSFA-HFD (diet enriched with ∼30 g (5E%) saturated MCFAs)